# PACIFIC-5 (NCT03706690)

> A Study of Durvalumab as Consolidation Therapy in Non-Small Cell Lung Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03706690
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: AstraZeneca
- Conditions: Carcinoma, Non-Small-Cell Lung
- Interventions: Durvalumab; Placebo
- Enrollment: 407
- Primary outcome: Progression-Free Survival (PFS) (Modified Intent-to-Treat [mITT] Set)

## Commentary we found

- Podcasts: 4
- X threads: 4
- YouTube: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pacific-5-nct03706690

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03706690", "email": "<work email>"}; the inbox owner confirms by the emailed link.